Physician profile
Debra A Wodecki
NPI 1598760407
$13,191.82
in general payments reported to CMS, 2019-2025
59 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $1,269 · 2021: $1,569 · 2022: $2,121 · 2023: $2,412 · 2024: $2,282 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,844.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,102.11 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $2,151.59 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,647.70 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,119.67 | 2019-2025 | |
| Ucb, INC. | $674.52 | 2019-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $350.56 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $309.70 | 2019-2025 | Benlysta |
| Radius Health, INC. | $308.70 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $233.92 | 2019-2023 | Krystexxa |
| Pfizer INC. | $222.44 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $196.25 | 2023-2025 | Xtampza, Belbuca |
| Actelion Pharmaceuticals US, INC. | $179.69 | 2019-2022 | |
| Novo Nordisk INC | $175.15 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Fresenius Kabi USA, LLC | $164.02 | 2023-2025 | Idacio |
| Astrazeneca Pharmaceuticals Lp | $159.43 | 2020-2025 | Saphnelo, Airsupra |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Wodecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.